MK-1064|cas 1207253-08-4|DC Chemicals

Cas No.:	1207253-08-4
Chemical Name:	Mk-1064
Synonyms:	MK-1064;MK1064;O812716S9E;5''-chloro-N-[(5,6-dimethoxypyridin-2-yl)methyl]-2,2':5',3''-terpyridine-3'-carboxamide;5-(5-Chloro-3-pyridyl)-N-((5,6-dimethoxy-2-pyridyl)methyl)-2-(2-pyridyl)pyridine-3-carboxamide;5''-Chloro-N-((5,6-dimethoxypyridin-2-yl)methyl)-2,2':5',3''-terpyridine-3'-carboxamide;CKTWQGHVNRYNCM-UHFFFAOYSA-N;Urokinase inhibitor 1;GTPL9306;BCP19608;BDBM50028059
SMILES:	ClC1=C([H])N=C([H])C(=C1[H])C1C([H])=NC(C2=C([H])C([H])=C([H])C([H])=N2)=C(C(N([H])C([H])([H])C2C([H])=C([H])C(=C(N=2)OC([H])([H])[H])OC([H])([H])[H])=O)C=1[H]
Formula:	C₂₄N₅O₃ClH₂₀
M.Wt:	461.9003
Sotrage:	4°C for 1 year, -20°C for more than 2 years

Description:

MK-1064 is a selective orexin 2 receptor antagonist (2-SORA) for the research of insomnia.target: 2-SORA [1]In vivo: MK-1064 promotes sleep and increases both rapid eye movement (REM) and non-REM (NREM) sleep in rats at OX2R occupancies higher than the range observed for dual orexin receptor antagonists. MK-1064 increases NREM and REM sleep in dogs without inducing cataplexy. The reference for animal administration is 30 mg/kg. [2]

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101
2018-0101

Cat. No.	Product name	Field of application
DC5017	Suvorexant	Suvorexant (MK-4305) is a potent, selective, and orally bioavailable antagonist of OX1R and OX2R currently under clinical investigation as a novel therapy for insomnia.Suvorexant is an analytical reference standard categorized as a diazepane sedative.Formulations containing suvorexant show abuse potential similar to zolpidem in recreational polydrug users with a history of sedative and psychedelic drug use.2 Suvorexant is regulated as a Schedule IV compound in the United States. This product is intended for use in analytical forensic applications.
DC9966	MK-1064	MK-1064 is a selective orexin 2 receptor antagonist (2-SORA) for the research of insomnia.
DC8173	Lemborexant(E2006)	Lemborexant (E-2006) is a dual antagonist of the orexin OX1 and OX2 receptors which is under development for treatment of insomnia.
DC7692	Almorexant HCl (Act-078573)	Almorexant(ACT078573) is a potent and competitive dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist with Ki values of 1.3 and 0.17 nM for OX1 and OX2, respectively.